New guidance on how and when to stop immunosuppressants in lupus patients

June 11, 2014, European League Against Rheumatism

A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that, for the majority of lupus patients who are in remission, it is possible to successfully stop immunosuppressant therapy without triggering a flare of their disease.1 Within two years, it was possible to stop the immunosuppressant in about 70% of clinically stable patients. Half were successful within three years, and this proportion remained stable for up to five years.1

Lupus is a chronic inflammatory disease that can affect any organ system, but mainly involves the joints, kidneys and skin.2 It typically follows a relapsing and remitting course; during a relapse, feel fatigue, and may develop rashes, arthritis (painful and swollen joints) and fever.2 Being able to stop long-term therapy in a lupus patient without inducing a relapse is an important treatment goal because of the potential side effects of these drugs, including the increased risk of infection and cancer.

In the USA, the average incidence of SLE has been estimated to range between 1.8 and 7.6 cases per 100,000 person-years.3 Incidence rates in Europe are similar, ranging from 3.3 to 4.8 per 100,000 person-years. The incidence of SLE is greater in Afro-Americans compared with Caucasians.4 SLE affects 10 times as many women as men.2

Lupus patients who develop serious or life-threatening problems such as kidney inflammation, lung or heart involvement, and central nervous system symptoms need more aggressive treatment, including high-dose corticosteroids such as prednisone, and immunosuppressants such as azathioprine (AZA), methotrexate (MTX) and mycophenolate mofetil (MMF).

"Until now, information on whether and how immunosuppressant therapy might be stopped in after achieving low disease activity or has been limited," said lead author Dr Zahi Touma, Assistant Professor of Medicine, Clinician-Scientist, Division Of Rheumatology, University of Toronto, Canada.

"The results from our study provide useful guidance on how best to stop the immunosuppressant without triggering a flare. For example, patients who discontinued their immunosuppressant more slowly were less likely to flare within two years," Dr Touma explained. "Those lupus patients who were serologically active at the time the immunosuppressant was stopped were much more likely to flare on follow-up visits," he added.

Out of a total population of 1,678 patients registered at the Toronto Lupus Clinic, 973 had been prescribed an immunosuppressant; and 99 had stopped taking it, of which 56 had been on AZA, 25 on MTX, and 18 on MMF. Of the 99 patients who stopped their immunosuppressant, 25 flared within two years (16 on AZA; 7 on MTX and 2 on MMF; p=0.31); 17 patients experienced a flared after year two.

Comparing patients who flared within two years to those who did not, the percentage of patients with positive serology† at the time their immunosuppressant was stopped was greater in those who flared, 68% vs. 42% (p=0.04).

In the no flare group, the length of time from the start of tapering to stopping the immunosuppressant was 1.8±1.8 years, significantly slower than the 0.9±0.9 years in the group who did experience a flare (p=0.002).

At the start of tapering, the mean age of the patients was 40.4±13.1 and mean disease duration was 11.4±9.4 years. 46 of the patients had follow-up available beyond two years; 32 were followed beyond three years, 26 beyond four years and 24 beyond five years. Using a Kaplan-Meier curve for the time to flare, at one, two, three, four and five years, the percentage of patients who flared was 17%, 30%, 46%, 49% and 51% respectively.

The analysis for this study was conducted on all patients seen in the Toronto Lupus Clinic in whom an immunosuppressant was tapered and then stopped. To be included, the lupus patient had to be in clinical remission: defined as no activity in the clinical SLE Disease Activity Index-2000 (SLEDAI-2K) descriptors‡ and an absence of proteinuria or lupus-related thrombocytopenia and leukopenia, and also to be taking ≤7.5mg of prednisone per day.

Three time points were identified for each patient:

  • the start of tapering defined as the first visit with a decrease of at least 25% in the dose of immunosuppressant
  • the day the immunosuppressant was completely stopped
  • the end of the study - defined as the date of flare, or last clinic visit after the immunosuppressant was stopped.

Flare was defined as the introduction of a new immunosuppressant, or any increase of prednisone dosage in the context of clinically active lupus.

Flare was evaluated within the first two years from the immunosuppressant being stopped, and also at any time after the immunosuppressant was stopped.

Explore further: Study: Mycophenolate is superior to azathioprine as treatment for lupus nephritis

Related Stories

Study: Mycophenolate is superior to azathioprine as treatment for lupus nephritis

November 16, 2011
A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.

Continued treatment for lupus may boost survival of those patients with end-stage kidney disease

September 20, 2011
Researchers at Albert Einstein College of Medicine of Yeshiva University have shown that close supervision by rheumatologists and the use of immunosuppressant drugs improve the survival of lupus patients with end-stage kidney ...

Kidney involvement, high anti-dsDNA predict lupus flares

July 2, 2013
(HealthDay)—Kidney involvement and high anti-double stranded (ds) DNA are independent predictors of moderate-severe lupus flare, according to research published online June 10 in Arthritis & Rheumatism.

The American College of Rheumatology issues guidelines for management of lupus nephritis

May 3, 2012
The American College of Rheumatology (ACR) has issued newly created guidelines for the screening, treatment, and management of lupus nephritis—a severe manifestation of systemic lupus erythematosus (SLE) where the disease ...

Research: Lupus drugs carry no significant cancer risk for patients

January 24, 2013
People who take immunosuppressive drugs to treat lupus do not necessarily increase their cancer risk according to new research led by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC). ...

Recommended for you

Osteoarthritis could be treated as two diseases, scientists reveal

January 10, 2018
Scientists at The University of Manchester have discovered that most people with osteoarthritis can be subdivided into two distinct disease groups, with implications for diagnosis and drug development.

US arthritis prevalence is much higher than current estimates

November 27, 2017
New research indicates that the prevalence of arthritis in the United States has been substantially underestimated, especially among adults

Maintaining sufficient vitamin D levels may help to prevent rheumatoid arthritis

November 20, 2017
Maintaining sufficient vitamin D levels may help to prevent the onset of inflammatory diseases like rheumatoid arthritis, research led by the University of Birmingham has discovered.

Old World monkeys could be key to a new, powerful rheumatoid arthritis therapy

November 16, 2017
In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa. It was ...

Study lists foods for fighting rheumatoid arthritis symptoms and progression

November 8, 2017
A list of food items with proven beneficial effects on the progression and symptoms of rheumatoid arthritis is provided in a new study published today in Frontiers in Nutrition. The authors suggest incorporating these foods ...

Prototype equipment can detect rheumatoid arthritis

September 28, 2017
According to a first clinical study published in the scientific journal Photoacoustics, the University of Twente and various European partners have designed a device that shows the difference between healthy fingers and arthritic ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.